Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Elisabeth Livingstone, Lisa Zimmer, Jessica C. Hassel, Michael Fluck, Thomas Eigentler, Carmen Loquai, Sebastian Haferkamp, Ralf Gutzmer, Friedegund Meier, Peter Mohr, Axel Hauschild, Bastian Schilling, Christian Menzer, Felix Kiecker, Edgar Dippel, Alexander Roesch, Mirjana Ziemer, Beate Conrad, Silvia Körner, Christine Windemuth-Kieselbach, Leonora Schwarz, Claus Garbe, Jürgen C. Becker, Dirk Schadendorf, Elisabeth Livingstone, Lisa Zimmer, Jessica C. Hassel, Michael Fluck, Thomas Eigentler, Carmen Loquai, Sebastian Haferkamp, Ralf Gutzmer, Friedegund Meier, Peter Mohr, Axel Hauschild, Bastian Schilling, Christian Menzer, Felix Kiecker, Edgar Dippel, Alexander Roesch, Mirjana Ziemer, Beate Conrad, Silvia Körner, Jan‐Christoph Simon, Rudolf Herbst, Carola Berking, Jochen Utikal, Sabine Sell, Uwe M. Martens, Patrick Terheyden, Rudolf Stadler, Christine Windemuth-Kieselbach, Leonora Schwarz, Claus Garbe, Jürgen C. Becker, Dirk Schadendorf